16 September 2026 editorial review · Item
Medtronic Guardian 4: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Thriving evidence review — 16 September 2026
Record: Medtronic Guardian 4
Scope and findings:
- Read clinical continued-access and real-world paper: 176 continued-access participants and 36,303 real-world users, calibration-free Guardian 4 with 780G; reported pivotal MARD 10.8%. Cross-study MARD is not a head-to-head sensor ranking; regional stock not checked.
Primary sources checked:
Limits: The review is restricted to the scopes above. Historical efficacy estimates, editorial scoring and country-specific access were not fully reverified unless expressly stated. A manufacturer or conference report retains that evidence level.